H.C. Wainwright initiated coverage of Compugen (CGEN) with a Buy rating and $4 price target The firm says the company’s immuno-oncology pipeline “offers multiple shots on goal.” Compugen holds mid-single-digit royalty rights and AstraZeneca estimates peak sales potential of more than $5B, implying a peak royalty stream of over $200M, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEN:
- Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca
- Compugen and AstraZeneca agree to monetize rilvegostomig future royalties
- Compugen Reports Q3 2025 Results and Clinical Progress
- Compugen’s Earnings Call: Strategic Focus Amid Financial Challenges
- Compugen Reports Q3 2025 Results and Advances Clinical Trials